CompanyVSTMNasdaqNeedham, MA

Verastem, Inc.

Verastem Oncology develops small molecule inhibitors targeting RAS/MAPK pathway-driven cancers.

SEC EDGAR ClinicalTrials.gov verastem.com

S-1Aug 28Latest SEC filing

Sep 17Latest story

September 2026

UVA registers Phase 1b/2 trial of Verastem's avutometinib/defactinib in pancreatic cancer

Sep 17Trial updateavutometinib defactinib

August 2026

Verastem amends Oberland note agreement, adds new revenue-linked notes tranche

Aug 6Regulatory decisionVerastem, Inc.

Verastem starts dosing in all three VS-7375 registration trials, secures added $75M financing

Aug 6Quarterly updateVerastem, Inc.VS-7375

Verastem registers open-label extension study for avutometinib-defactinib in LGSOC

Aug 5Trial updateavutometinib defactinib

July 2026

ROCKIF trial of defactinib in ovarian cancer terminated for lost funding; results posted

Jul 31Trial updatedefactinib Verastem, Inc.